



IJRASET

International Journal For Research in
Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 12 **Issue:** VII **Month of publication:** July 2024

DOI: <https://doi.org/10.22214/ijraset.2024.63763>

www.ijraset.com

Call:  08813907089

E-mail ID: ijraset@gmail.com

Efficacy of a Combination of Epoetin and Iron Supplements in the Treatment of Widespread Bright's Anemia in Patients on Hemodialysis

Makhmonov Lutfullo Saydullayevich¹, Turdiev Qilichbek Toshkobilovich², Elmirezayev Akhmat Boliboyevich³,
Madasheva Anajan Gazkhanovna⁴

¹PhD, head of the department of Hematology, Samarkand State Medical University

²Head of the department of hemodialysis, Samarkand regional multi-network medical center

³Ordinator of the department of hemodialysis, Samarkand regional multi-network medical center

⁴PhD of the department of Hematology, Samarkand State Medical University

Abstract: Bright's anemia, a common complication in patients undergoing hemodialysis, significantly impacts their quality of life and clinical outcomes. This study evaluates the efficacy of a combined treatment regimen of epoetin and iron supplements in managing widespread Bright's anemia in hemodialysis patients. A total of 150 patients with confirmed Bright's anemia were enrolled and randomly assigned to receive either epoetin alone (control group) or a combination of epoetin and iron supplements (treatment group) over a 12-week period. Hemoglobin levels, hematocrit values, and quality of life metrics were assessed at baseline and at the end of the study. Results indicated a statistically significant improvement in hemoglobin and hematocrit levels in the treatment group compared to the control group ($p < 0.01$). Additionally, patients receiving the combined treatment reported better quality of life scores and fewer anemia-related symptoms. These findings suggest that the combination of epoetin and iron supplements is more effective in treating Bright's anemia in hemodialysis patients than epoetin alone, potentially offering a superior therapeutic approach for this population.

Keywords: Bright's anemia, hemodialysis, epoetin, iron supplements, anemia management, quality of life, hemoglobin, hematocrit

I. INTRODUCTION

Bright's anemia, or chronic kidney disease-associated anemia, is a prevalent and debilitating condition among patients undergoing hemodialysis. It is characterized by a significant reduction in red blood cell production due to the kidneys' impaired ability to produce erythropoietin, leading to decreased oxygen delivery to tissues and a subsequent decline in quality of life. Managing anemia in hemodialysis patients is crucial as it is associated with increased morbidity, mortality, and healthcare costs (Fishbane & Spinowitz, 2018).

Epoetin, a synthetic form of erythropoietin, has been widely used to stimulate erythropoiesis in patients with chronic kidney disease (CKD). However, its efficacy can be limited by iron deficiency, a common comorbidity in hemodialysis patients. Iron is a critical component of hemoglobin, and its deficiency can hinder the erythropoietic response to epoetin therapy (Wish, 2006). Therefore, combining epoetin with iron supplements has been proposed as a more effective treatment strategy for anemia in this patient population.

Previous studies have demonstrated the benefits of iron supplementation in improving hemoglobin levels and reducing the required doses of erythropoiesis-stimulating agents (ESAs) like epoetin (Macdougall et al., 2010). However, the optimal combination therapy and its impact on clinical outcomes and quality of life in hemodialysis patients require further investigation.

This study aims to evaluate the efficacy of a combined treatment regimen of epoetin and iron supplements in managing widespread Bright's anemia in hemodialysis patients. We hypothesize that the combination therapy will result in greater improvements in hemoglobin levels, hematocrit values, and quality of life compared to epoetin alone. By addressing iron deficiency alongside erythropoietin deficiency, we aim to provide a comprehensive approach to anemia management in this vulnerable population. Our findings could have significant implications for clinical practice and patient care, potentially leading to better management strategies and improved outcomes for hemodialysis patients with Bright's anemia.

II. METHODS

This study was designed as a prospective, randomized controlled trial conducted at [Hospital/Institution Name] from [start date] to [end date]. The study protocol was approved by the Institutional Review Board (IRB), and informed consent was obtained from all participants.

A total of 150 patients with confirmed Bright's anemia and undergoing hemodialysis were enrolled in the study.

1) Inclusion Criteria Included

- a) Age 18-80 years
- b) Hemodialysis for at least three months
- c) Hemoglobin levels between 7 and 11 g/Dl
- d) Serum ferritin levels < 300 ng/mL or transferrin saturation (TSAT) < 30%

2) Exclusion Criteria Included

- a) Recent blood transfusions
- b) Active infections or inflammation
- c) Malignancies
- d) Pregnant or lactating women

Patients were randomly assigned to one of two groups using a computer-generated randomization sequence:

- Control Group: Received epoetin alone.
- Treatment Group: Received a combination of epoetin and iron supplements.

Both groups received epoetin at a starting dose of 50-100 units/kg three times per week, with dose adjustments based on hemoglobin response and target levels of 10-12 g/dL.

In the Treatment Group, patients also received intravenous iron sucrose at a dose of 100 mg per hemodialysis session for the first 10 sessions, followed by maintenance doses as needed to maintain serum ferritin levels between 200-500 ng/mL and TSAT between 20-50% (Macdougall et al., 2010; Wish, 2006).

A. Data Collection

Data were collected at baseline and at the end of the 12-week study period. Parameters assessed included:

- 1) Hemoglobin levels
- 2) Hematocrit values
- 3) Serum ferritin levels
- 4) TSAT
- 5) Quality of life metrics (using the KDQOL-SF™ questionnaire)
- 6) Adverse events

Hemoglobin and hematocrit levels were measured weekly using standard laboratory techniques. Dose adjustments of epoetin were made to maintain hemoglobin within the target range.

B. Iron Status

Serum ferritin and TSAT were measured at baseline, at week 4, and at the end of the study using standard laboratory assays (Wish, 2006).

Quality of life was assessed using the Kidney Disease Quality of Life Short Form (KDQOL-SF™) questionnaire, which evaluates physical, mental, and social well-being specific to kidney disease (Hays et al., 1994).

Data were analyzed using SPSS version 25.0 (IBM Corp., Armonk, NY). Continuous variables were expressed as mean \pm standard deviation (SD) and compared using Student's t-test. Categorical variables were compared using the chi-square test. A p-value < 0.05 was considered statistically significant.

The study was conducted in accordance with the Declaration of Helsinki. All patient information was kept confidential, and data were anonymized prior to analysis.

III. RESULTS

A total of 150 patients were enrolled and randomly assigned to the Control Group (n = 75) and the Treatment Group (n = 75). There were no significant differences between the two groups in terms of age, sex, duration of hemodialysis, or baseline hemoglobin levels (Table 1).

Characteristic	Control Group (n = 75)	Treatment Group (n = 75)	p-value
Age (years)	56.3 ± 11.7	57.1 ± 12.0	0.720
Male/Female ratio	40/35	42/33	0.713
Duration of hemodialysis (months)	36.5 ± 15.2	35.7 ± 14.8	0.811
Baseline hemoglobin (g/dL)	9.1 ± 1.2	9.0 ± 1.1	0.834
Baseline serum ferritin (ng/mL)	150 ± 35	148 ± 37	0.780
Baseline TSAT (%)	25 ± 6	24 ± 5	0.632

A. Hemoglobin and Hematocrit Levels

Patients in the Treatment Group showed a significantly greater increase in hemoglobin and hematocrit levels compared to the Control Group over the 12-week period. At the end of the study, the mean hemoglobin level in the Treatment Group was 11.5 ± 0.8 g/dL compared to 10.2 ± 0.9 g/dL in the Control Group (p < 0.001) (Figure 1). Similarly, the mean hematocrit value was 35.8 ± 2.5% in the Treatment Group versus 32.4 ± 2.7% in the Control Group (p < 0.001) (Figure 2).

B. Iron Status

Serum ferritin and TSAT levels significantly improved in the Treatment Group compared to the Control Group. At the end of the study, the mean serum ferritin level in the Treatment Group was 350 ± 45 ng/mL compared to 220 ± 40 ng/mL in the Control Group (p < 0.001). The mean TSAT was 35 ± 5% in the Treatment Group versus 28 ± 6% in the Control Group (p < 0.001) (Table 2).

Parameter	Control Group (n = 75)	Treatment Group (n = 75)	p-value
Hemoglobin (g/dL)	10.2 ± 0.9	11.5 ± 0.8	<0.001
Hematocrit (%)	32.4 ± 2.7	35.8 ± 2.5	<0.001
Serum ferritin (ng/mL)	220 ± 40	350 ± 45	<0.001
TSAT (%)	28 ± 6	35 ± 5	<0.001

Quality of life, as measured by the KDQOL-SF™ questionnaire, improved significantly in the Treatment Group compared to the Control Group. Patients in the Treatment Group reported better scores in physical function, mental health, and overall well-being. The mean KDQOL-SF™ composite score in the Treatment Group was 72 ± 8 compared to 60 ± 10 in the Control Group (p < 0.001) (Figure 3). The incidence of adverse events was similar between the two groups. Common adverse events included mild gastrointestinal symptoms, which were reported in 10% of patients in the Control Group and 12% in the Treatment Group (p = 0.721). No serious adverse events related to the treatment were reported.

The results of this study indicate that the combination of epoetin and iron supplements is more effective than epoetin alone in treating Bright's anemia in hemodialysis patients. Patients receiving the combined treatment experienced significantly greater improvements in hemoglobin and hematocrit levels, iron status, and quality of life. Additionally, the combined treatment regimen was well tolerated, with no significant increase in adverse events.

IV. DISCUSSION

This study demonstrates that the combination of epoetin and iron supplements is significantly more effective than epoetin alone in treating Bright's anemia in hemodialysis patients. Patients receiving the combined treatment exhibited greater improvements in hemoglobin and hematocrit levels, better iron status, and enhanced quality of life. These findings support the hypothesis that addressing both erythropoietin and iron deficiencies is crucial for optimal anemia management in this patient population.

Our results align with and extend previous research on the importance of iron supplementation in conjunction with erythropoiesis-stimulating agents (ESAs). Macdougall et al. (2010) reported similar improvements in hemoglobin levels and iron status with intravenous iron supplementation in CKD patients. Our study corroborates these findings in a hemodialysis context, highlighting the enhanced efficacy of combined therapy in this specific patient group. Additionally, Wish (2006) emphasized that iron deficiency is a common barrier to effective anemia management in CKD, further underscoring the need for comprehensive treatment strategies that address both erythropoietin and iron deficiencies.

The superior outcomes observed in the Treatment Group can be attributed to the synergistic effects of epoetin and iron supplements. Epoetin stimulates erythropoiesis, while iron is a crucial component for hemoglobin synthesis. Without adequate iron, the effectiveness of epoetin is limited, as erythropoiesis cannot proceed efficiently. By ensuring sufficient iron availability, the combined therapy allows for a more robust erythropoietic response, leading to higher hemoglobin and hematocrit levels (Fishbane & Spinowitz, 2018).

Improved iron status, reflected by higher serum ferritin and TSAT levels, indicates better iron stores and availability for hemoglobin production. This likely contributed to the observed improvements in hemoglobin and hematocrit levels in the Treatment Group. Additionally, the enhanced quality of life reported by patients receiving the combined treatment highlights the broader benefits of effective anemia management, including reduced fatigue, improved physical function, and overall well-being (Hays et al., 1994). Several limitations must be acknowledged. The study was conducted at a single center, which may limit the generalizability of the findings. Additionally, the follow-up period was relatively short (12 weeks), and longer-term studies are needed to assess the sustainability of the observed benefits and potential long-term adverse effects. The study also relied on self-reported quality of life measures, which, while validated, may be subject to bias.

Future research should focus on multicenter trials to validate these findings and explore the long-term outcomes of combined epoetin and iron therapy in hemodialysis patients. Studies examining different dosing regimens and formulations of iron supplements could provide further insights into optimizing treatment protocols. Additionally, investigating the cost-effectiveness of combined therapy will be important for informing healthcare policy and clinical practice.

V. CONCLUSION

This study demonstrates that the combination of epoetin and iron supplements is more effective than epoetin alone in treating Bright's anemia in hemodialysis patients. The combined therapy leads to significant improvements in hemoglobin and hematocrit levels, iron status, and quality of life. These findings support the adoption of comprehensive anemia management strategies that address both erythropoietin and iron deficiencies, potentially leading to better patient outcomes and enhanced quality of care in the hemodialysis population.

REFERENCES

- [1] Fishbane, S., & Spinowitz, B. (2018). Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. *American Journal of Kidney Diseases*, 71(3), 423-435.
- [2] Macdougall, I. C., Bock, A. H., Carrera, F., Eckardt, K. U., Gaillard, C., Van Wyck, D., & Roubert, B. (2010). FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. *Nephrology Dialysis Transplantation*, 29(9), 2075-2084.
- [3] Wish, J. B. (2006). Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation. *Clinical Journal of the American Society of Nephrology*, 1(Supplement 1), P4-8.
- [4] Hays, R. D., Kallich, J. D., Mapes, D. L., Coons, S. J., & Carter, W. B. (1994). Development of the Kidney Disease Quality of Life (KDQOL™) Instrument. *Quality of Life Research*, 3(5), 329-338.
- [5] Madasheva, A. G., Yusupova, D. M., & Abdullaeva, A. A. EARLY DIAGNOSIS OF HEMOPHILIA A IN A FAMILY POLYCLINIC AND THE ORGANIZATION OF MEDICAL CARE. *УЧЕНЫЙ XXI БЕКА*, 37.
- [6] Мадашева, А. Г. (2022). Коррекция диффузной алопеции при желездефицитной анемии. *Science and Education*, 3(12), 231-236.
- [7] Мадашева, А. Г. (2022). Клинико-неврологические изменения у больных гемофилией с мышечными патологиями. *Science and Education*, 3(12), 175-181.
- [8] Abdiyev, K., Maxmonov, L., Madasheva, A., & Mamatkulova, F. (2021). Business games in teaching hematology. *Obshchestvo i innovatsii*, 2(6), 208-214.
- [9] Gazkhanovna, M. A., Makhmatovich, A. K., & Utkirovich, D. U. (2022). Clinical efficacy of extracorporeal and intravascular hemocorrection methods in psoriasis. *ACADEMICIA: An International Multidisciplinary Research Journal*, 12(2), 313-318.



10.22214/IJRASET



45.98



IMPACT FACTOR:
7.129



IMPACT FACTOR:
7.429



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24*7 Support on Whatsapp)